Yes, the report was not something to stand up and cheer about, but that one section: "...the use of PBT2 at lower doses (as currently permitted by the FDA), or using PBT2 for acute indications requiring shorter term use," gives me hope. Pivalde, it seems they might be coming to their senses, or may have actually listened to your recommendations.
The dim hope that Europe would not follow the FDA's lead has been trashed. PBT2's use with HD has been zapped because of its toxicity (and questionable reversibility) with dogs not humans. Unfortunately, who's to say that a dog study with PBT434 or PBT512 would come out any better. The "acute indications" with allowable doses seems the better and faster course. I hope they begin to focus more energy in this direction.
On another note:
Here in the US PRAN today is at $ 1.97 (US) /share. Surprisingly the book value is listed at $ 2.64 (US) /share. Does that seem accurate?
" PBT2 for acute indications ", page-2
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $4.579K | 1.526M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 749591 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 133062022 | 26 |
View Market Depth
| Last trade - 14.03pm 13/09/2024 (20 minute delay) ? |
| ATH (ASX) Chart |